efficacy and tolerability of the association of sibutramine and orlistat for six months in overweight and obese patients疗效和耐受性协会的西布曲明和奥利司他六个月超重和肥胖患者.pdfVIP

Hindawi Publishing Corporation Journal of Obesity Volume 2010, Article ID 602537, 5 pages doi:10.1155/2010/602537 Clinical Study Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients 1 2 2 ˆ 2 Alfredo Halpern, Renata B. Pepe, Ana Paola Monegaglia, Monica Beyruti, Maria Edna de Melo,1 and Marcio C. Mancini1 1 Group of Obesity Metabolic Syndrome, Endocrinology Service, Hospital das Clınicas, Faculty of Medicine, ´ University of Sao Paulo, 05410-000 Sao Paulo, Brazil ˜ 2 Department of Nutrition and Dietitian, Clınica Alfredo Halpern, 05410-000 Sao Paulo, Brazil ´ ˜ Correspondence should be addressed to Alfredo Halpern, alfredo.halpern@.br Received 24 June 2009; Revised 17 November 2009; Accepted 3 December 2009 Academic Editor: Renato Pasquali Copyright © 2010 Alfredo Halpern et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To assess the efficacy and tolerability of the association sibutramine (10–20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were assessed every 2 weeks during a period of 3 and 6 mo